| Primary |
| Hodgkin's Disease |
46.9% |
| Hiv Infection |
20.4% |
| Castleman's Disease |
16.3% |
| Hodgkin's Disease Mixed Cellularity Stage Iii |
10.2% |
| Bladder Cancer |
2.0% |
| Hodgkin's Lymphoma |
2.0% |
| Neoplasm Malignant |
2.0% |
|
| Tachycardia |
13.3% |
| Constipation |
6.7% |
| Disease Progression |
6.7% |
| Large Intestine Perforation |
6.7% |
| Malaria |
6.7% |
| Medication Error |
6.7% |
| Neuropathy Peripheral |
6.7% |
| Neutrophil Count Decreased |
6.7% |
| Non-hodgkin's Lymphoma |
6.7% |
| Pain In Jaw |
6.7% |
| Pyrexia |
6.7% |
| Sensory Loss |
6.7% |
| Toxicity To Various Agents |
6.7% |
| Wrong Drug Administered |
6.7% |
|
| Secondary |
| Hodgkin's Disease |
63.3% |
| Diffuse Large B-cell Lymphoma |
5.9% |
| Langerhans' Cell Histiocytosis |
4.1% |
| Hiv Infection |
2.8% |
| Product Used For Unknown Indication |
2.5% |
| Non-hodgkin's Lymphoma |
2.4% |
| Drug Use For Unknown Indication |
2.3% |
| Ovarian Cancer |
2.1% |
| Chemotherapy |
2.1% |
| Haematological Malignancy |
1.5% |
| Castleman's Disease |
1.4% |
| Prophylaxis |
1.3% |
| Bladder Cancer |
1.3% |
| Hodgkin's Disease Nodular Sclerosis Stage Unspecified |
1.3% |
| Malignant Histiocytosis |
1.2% |
| Lymphoma |
1.1% |
| Non-hodgkin's Lymphoma Stage Iv |
1.0% |
| Testicular Germ Cell Cancer |
1.0% |
| Hodgkin's Disease Stage Ii |
0.8% |
| Hodgkin's Disease Stage Iv |
0.8% |
|
| Pulmonary Toxicity |
21.4% |
| Febrile Neutropenia |
9.3% |
| Hypothyroidism |
7.1% |
| Neutropenia |
7.1% |
| Sepsis |
6.2% |
| Pyrexia |
5.0% |
| Pancytopenia |
4.3% |
| Acute Myeloid Leukaemia |
4.0% |
| Hodgkin's Disease Recurrent |
4.0% |
| Toxicity To Various Agents |
4.0% |
| Vomiting |
3.7% |
| Neutrophil Count Decreased |
3.4% |
| Diffuse Large B-cell Lymphoma |
3.1% |
| White Blood Cell Count Decreased |
3.1% |
| Cardiomyopathy |
2.8% |
| Colon Cancer |
2.5% |
| Interstitial Lung Disease |
2.2% |
| Neuropathy Peripheral |
2.2% |
| Pulmonary Embolism |
2.2% |
| Tachycardia |
2.2% |
|
| Concomitant |
| Hodgkin's Disease |
19.4% |
| Diffuse Large B-cell Lymphoma |
18.0% |
| Transitional Cell Carcinoma |
10.9% |
| Chemotherapy |
10.0% |
| Prophylaxis |
7.1% |
| Non-hodgkin's Lymphoma |
4.8% |
| Product Used For Unknown Indication |
4.8% |
| Pseudolymphoma |
4.6% |
| Drug Use For Unknown Indication |
4.3% |
| Neutropenia |
3.8% |
| Eczema |
3.0% |
| Gastrooesophageal Cancer |
1.5% |
| Hodgkin's Disease Stage Iii |
1.3% |
| Bone Disorder |
1.2% |
| Prostate Cancer |
1.2% |
| Disease Progression |
1.0% |
| Abdominal Pain Upper |
0.8% |
| Arrhythmia |
0.8% |
| Constipation |
0.8% |
| Depression |
0.8% |
|
| Febrile Bone Marrow Aplasia |
7.7% |
| Febrile Neutropenia |
6.7% |
| Sepsis |
6.7% |
| Vomiting |
6.7% |
| Aplasia |
5.8% |
| Neutropenic Sepsis |
5.8% |
| Pulmonary Toxicity |
5.8% |
| Syncope |
5.8% |
| Thrombocytopenia |
5.8% |
| Wound Infection |
5.8% |
| Diarrhoea |
4.8% |
| Interstitial Lung Disease |
4.8% |
| Gastrointestinal Perforation |
3.8% |
| Neutropenia |
3.8% |
| Respiratory Failure |
3.8% |
| Weight Decreased |
3.8% |
| White Blood Cell Count Decreased |
3.8% |
| Anaemia |
2.9% |
| Dyspnoea |
2.9% |
| Leukopenia |
2.9% |
|
| Interacting |
| Hiv Infection |
28.1% |
| Hodgkin's Disease |
27.5% |
| Product Used For Unknown Indication |
15.2% |
| Drug Use For Unknown Indication |
11.2% |
| Cardiomyopathy |
6.7% |
| Antibiotic Prophylaxis |
3.4% |
| Prophylaxis |
2.2% |
| Antifungal Prophylaxis |
1.7% |
| Chemotherapy |
1.1% |
| Immunosuppressant Drug Level Decreased |
1.1% |
| Multiple-drug Resistance |
1.1% |
| Bone Pain |
0.6% |
|
| Neutropenia |
23.5% |
| Pyrexia |
23.5% |
| Neurotoxicity |
17.6% |
| Drug Interaction |
11.8% |
| Abdominal Pain |
5.9% |
| Drug Level Decreased |
5.9% |
| Megacolon |
5.9% |
| Potentiating Drug Interaction |
5.9% |
|
